A notable institutional investor has established a new position in Viking Therapeutics, providing fresh momentum for the biopharmaceutical stock. This development precedes a busy schedule of investor conferences throughout September where the company’s management is slated to present.
New Investment from Landscape Capital
Investment firm Landscape Capital Management L.L.C. has disclosed a new holding in Viking Therapeutics, acquiring 10,003 shares valued at approximately $242,000. Moves of this nature from institutional players are often viewed as a sign of confidence and can signal anticipation of upcoming corporate developments, focusing market attention on the stock’s near-term potential.
Packed September Event Calendar
The company is set to engage extensively with the investment community this month, with presentations scheduled at several major healthcare conferences. These events frequently serve as catalysts for stock movement. Viking Therapeutics’ management will present at the following forums:
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
- Cantor Global Healthcare Conference: September 3-5
- Morgan Stanley Global Healthcare Conference: September 8-10
- Bernstein Healthcare Forum: September 23-25
- Stifel Virtual Cardiometabolic Forum: September 30
To ensure broad dissemination of the presented information, the webcasts for the Morgan Stanley and Bernstein conferences will be made available on the corporate website.
Clinical Progress Underpins Investor Interest
This heightened market activity is supported by significant recent clinical achievements. In August 2025, Viking reported positive topline results from its Phase 2 VENTURE study evaluating the VK2735 tablet for the treatment of obesity. The trial successfully met all its primary and secondary endpoints, demonstrating statistically significant weight reductions compared to a placebo. Building on prior success with an injectable formulation, the company has also initiated its Phase 3 VANQUISH registration studies for VK2735 in obesity.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from January 23 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 23.
Viking Therapeutics: Buy or sell? Read more here...
